Singapore
Tessa Therapeutics Ltd is a clinical-stage biotechnology company based in Singapore, focusing on developing autologous and allogeneic cell therapies for the treatment of cancer. The company's autologous CD30-CAR-T therapy TT11 is currently in Phase 2 and 1b clinical trials as a potential treatment for relapsed or refractory classical Hodgkin lymphoma. It has been granted RMAT designation by the FDA and access to the PRIME scheme by the European Medicine Agency. In addition, Tessa is advancing an allogeneic "off-the-shelf" cell therapy platform targeting a broad range of cancers and is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. The company has its global headquarters in Singapore, where it has built a state-of-the-art, commercial cell therapy manufacturing facility.
The most recent investment received by Tessa Therapeutics Ltd was a SGD100.00K grant investment on 19 May 2023, with Cytiva BioChallenge as the investor. Tessa's innovative approach and promising developments in cell therapy for cancer treatment make it an intriguing prospect for investors looking to support groundbreaking biotechnology advancements.
For more information on Tessa, visit www.tessacell.com.
